Vitamin a Palmitate
CAS 79-81-2
Vitamin a Palmitate (CAS 79-81-2) is a Phase 4 pharmaceutical compound with 4 bioactivity targets and 1,665 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 29405.945161290325 nM | 31 | - |
| - | Potency | 33168.73333333333 nM | 9 | - |
| Beta-lactoglobulin Unclassified |
Kd | 7.44 | - | Bos taurus |
| Retinol-binding protein 4 Secreted |
Kd | 6.74 | - | Homo sapiens |
| Amyloid beta A4 protein Unclassified |
IC50 | 6.75 | - | Homo sapiens |
| Alpha-synuclein Transporter |
IC50 | 6.72 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Presbyacusis | 31 | 155.563 | 10036626 |
| Pleural thickening | 31 | 152.251 | 10035616 |
| Blood magnesium increased | 31 | 147.179 | 10005655 |
| Pleural fibrosis | 31 | 141.415 | 10035600 |
| Deafness neurosensory | 31 | 127.753 | 10011891 |
| Epigastric discomfort | 31 | 124.75 | 10053155 |
| Hypervitaminosis A | 14 | 124.403 | 10020916 |
| Cyst | 31 | 103.719 | 10011732 |
| Osteopenia | 31 | 96.297 | 10049088 |
| Blood potassium increased | 31 | 86.604 | 10005725 |
| Dry eye | 32 | 78.115 | 10013774 |
| Skin lesion | 31 | 73.505 | 10040882 |
| Appendicolith | 19 | 69.937 | 10074458 |
| Blood phosphorus increased | 19 | 65.262 | 10050196 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| RETINYL PALMITATE | 35406 | SU | MTHSPL |
| VITAMIN A PALMITATE | 35406 | SU | MTHSPL |
| Vitamin A Palmitate | 35406 | SU | MTHSPL |
| vitamin a palmitate | 35406 | SU | MTHSPL |
| vitamin A palmitate | 35406 | PIN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Vitamin a Palmitate used for in pharmaceutical contexts?
Vitamin a Palmitate (CAS 79-81-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Vitamin a Palmitate?
Vitamin a Palmitate has 1,665 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Presbyacusis, Pleural thickening, Blood magnesium increased, Pleural fibrosis, Deafness neurosensory. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Vitamin a Palmitate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Retinyl Palmitate with EU status "restricted".
What clinical phase is Vitamin a Palmitate in?
Vitamin a Palmitate is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Vitamin a Palmitate?
Vitamin a Palmitate has 6 bioactivity rows in this page query. Rendered target entries include Beta-lactoglobulin, Retinol-binding protein 4, Amyloid beta A4 protein, Alpha-synuclein.